IMUC Stock Overview
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
EOM Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.27 |
52 Week High | US$0.40 |
52 Week Low | US$0.15 |
Beta | 1.38 |
1 Month Change | -8.67% |
3 Month Change | 29.20% |
1 Year Change | -21.74% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -46.29% |
Recent News & Updates
Recent updates
Shareholder Returns
IMUC | US Biotechs | US Market | |
---|---|---|---|
7D | 23.9% | -0.06% | 2.1% |
1Y | -21.7% | 9.8% | 30.4% |
Return vs Industry: IMUC underperformed the US Biotechs industry which returned 9.8% over the past year.
Return vs Market: IMUC underperformed the US Market which returned 30.4% over the past year.
Price Volatility
IMUC volatility | |
---|---|
IMUC Average Weekly Movement | 45.8% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMUC's share price has been volatile over the past 3 months.
Volatility Over Time: IMUC's weekly volatility has decreased from 55% to 46% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 4 | Irach Taraporewala | https://www.eompharma.com |
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases.
EOM Pharmaceuticals Holdings, Inc. Fundamentals Summary
IMUC fundamental statistics | |
---|---|
Market cap | US$31.02m |
Earnings (TTM) | -US$5.13m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.1x
P/E RatioIs IMUC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMUC income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$5.13m |
Earnings | -US$5.13m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.045 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -81.8% |
How did IMUC perform over the long term?
See historical performance and comparison